Buyback yield (TTM)
3.97%
Shareholder yield (TTM)
4.44%
5Y share count change
-5.6%
Buyback spend (TTM)
$3.19B
Cumulative buybacks
$23.49B
Key takeaways
- Regeneron Pharmaceuticals (REGN) repurchased about $3.19B of stock over the trailing twelve months.
- Diluted share count is down 5.6% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 3.21× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at -9.5% per year over the latest 5-year window.
- TTM repurchases used about 84% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Regeneron Pharmaceuticals (REGN)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Regeneron Pharmaceuticals (REGN)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Regeneron Pharmaceuticals (REGN)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Regeneron Pharmaceuticals (REGN)
Latest: $3.97B
Overview
In 2025, Regeneron Pharmaceuticals (REGN) buyback spend totalled $3.97B – grew 9.3% year-over-year.
Through 2020–2025 (5 years), Regeneron Pharmaceuticals buyback spend delivered a -9.5% annualised rate; sustaining 2 straight years of year-over-year growth.
Regeneron Pharmaceuticals buyback spend plunged from $6.53B in 2020 to $3.97B in 2025, a 39.2% drawdown.
The record annual buyback spend stands at $6.53B, reached in 2020; the historical low of $0.00 was recorded in 1991.
Regeneron Pharmaceuticals Buyback Spend 2025: $3.97B
Regeneron Pharmaceuticals posted buyback spend of $3.97B in 2025, grew 9.3% from 2024.
Regeneron Pharmaceuticals Buyback Spend 2024: $3.63B
In 2024, Regeneron Pharmaceuticals reported buyback spend of $3.63B, surged 62.5% from 2023.
Regeneron Pharmaceuticals Buyback Spend 2023: $2.23B
Regeneron Pharmaceuticals buyback spend in 2023 was $2.23B, declined 11.6% below 2022.
Regeneron Pharmaceuticals Buyback Spend 2022: $2.53B
2022's buyback spend for Regeneron Pharmaceuticals came in at $2.53B, declined 5.6% below 2021.
Regeneron Pharmaceuticals Buyback Spend 2021: $2.68B
Regeneron Pharmaceuticals buyback spend in 2021 was $2.68B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $3.97B | $993.70M | $2.98B | 5.00% | 0.11B | -5.6% | |
| 2024 | $3.63B | $982.80M | $2.65B | 4.73% | 0.12B | +1.2% | |
| 2023 | $2.23B | $885.00M | $1.35B | 2.39% | 0.11B | +0.2% | |
| 2022 | $2.53B | $725.00M | $1.80B | 3.28% | 0.11B | +1.2% | |
| 2021 | $2.68B | $601.70M | $2.08B | 3.99% | 0.11B | -2.5% | |
| 2020 | $6.53B | $432.00M | $6.10B | 12.82% | 0.12B | +0.4% | |
| 2019 | $463.90M | $464.30M | −$400.00K | 1.08% | 0.11B | -0.2% | |
| 2018 | $191.60M | $427.40M | −$235.80M | 0.45% | 0.11B | -1.0% | |
| 2017 | $301.70M | $507.28M | −$205.58M | 0.69% | 0.12B | -0.3% | |
| 2016 | $143.20M | $559.88M | −$416.68M | 0.34% | 0.12B | +0.9% | |
| 2015 | $160.54M | $459.05M | −$298.51M | 0.26% | 0.12B | +1.6% | |
| 2014 | $267.58M | $307.24M | −$39.65M | 0.57% | 0.11B | +2.0% | |
| 2013 | $195.09M | $198.40M | −$3.31M | 0.54% | 0.11B | -3.5% | |
| 2012 | $163.30M | $94.16M | $69.14M | 0.86% | 0.12B | +27.3% | |
| 2011 | $25.08M | $56.09M | −$31.02M | 0.49% | 0.09B | +9.3% | |
| 2010 | $3.80M | $39.90M | −$36.10M | 0.13% | 0.08B | +3.9% | |
| 2009 | $0.00 | $31.26M | −$31.26M | — | 0.08B | +1.2% | |
| 2008 | $0.00 | $32.52M | −$32.52M | — | 0.08B | +18.8% | |
| 2007 | $0.00 | $28.07M | −$28.07M | — | 0.07B | +14.4% | |
| 2006 | $0.00 | $0.00 | $0.00 | — | 0.06B | +3.6% | |
| 2005 | $0.00 | $0.00 | $0.00 | — | 0.06B | -0.4% | |
| 2004 | $888.00K | $0.00 | $888.00K | 0.17% | 0.06B | +11.3% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 0.05B | +14.8% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 0.04B | +4.4% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.04B | +19.7% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.04B | +11.8% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 0.03B | +1.4% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 0.03B | +6.9% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 0.03B | +18.5% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.02B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$3.97B
- 2024$3.63B
- 2023$2.23B
- 2022$2.53B
- 2021$2.68B
- 2020$6.53B
- 2019$463.90M
- 2018$191.60M
- 2017$301.70M
- 2016$143.20M
- 2015$160.54M
- 2014$267.58M
- 2013$195.09M
- 2012$163.30M
- 2011$25.08M
- 2010$3.80M
- 2009$0.00
- 2008$0.00
- 2007$0.00
- 2006$0.00
- 2005$0.00
- 2004$888.00K
- 2003$0.00
- 2002$0.00
- 2001$0.00
- 2000$0.00
- 1999$0.00
- 1998$0.00
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1993$0.00
- 1992$0.00
- 1991$0.00
Buybacks vs stock-based compensation for Regeneron Pharmaceuticals (REGN)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 3.21×.
Buybacks vs dividends (share of cash returned) for Regeneron Pharmaceuticals (REGN)
How Regeneron Pharmaceuticals splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $3.78B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation